Company Analysis
Sign in

Viatris Inc. (VTRS)

Nasdaq: VTRS · Pharmaceutical Preparations · Canonsburg, PA · filing with the SEC since 2019
Full chart Alerts Compare
Grade4.7
◀ Past 5.5● Present 4.9▶ Future 3.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

2,427 patents granted to the 37 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Viatris Inc.’s names, not what it holds today.

Patents granted
2,427
2,406 utility, 12 reissue, 7 design, 2 plant, 1976 to Dec 31, 2025
Granted in 2025
2
Against 11 in 2024 and 2 in 2023
Applications published
297
11 of them in 2025
Names they are printed under
37
a former name, a subsidiary, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals9
Organic fine chemistry6
Medical technology6
Control1
Handling1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name37 counted
The Upjohn Co. a former name
US, as the owner printed on each patent
2,180 granted
1 published
Mylan Inc. a subsidiary
US, as the owner printed on each patent. 15 more under the same name are not counted (printed in VN, printed in ES)
39 granted
39 published
Mylan Laboratories Limited a subsidiary
IN, as the owner printed on each patent. 7 more under the same name are not counted (printed in US)
39 granted
32 published
Generics [UK] Limited a subsidiary
GB, as the owner printed on each patent
31 granted
37 published
Mylan Pharmaceuticals Inc. a subsidiary
US, as the owner printed on each patent
24 granted
12 published
Mylan Technologies, Inc. a subsidiary
US, as the owner printed on each patent
13 granted
18 published
Mylan Inc. a subsidiary
named as the applicant on its applications, in US. 2 more under the same name are not counted (printed in CH)
0 granted
28 published
Oyster Point Pharma, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
28 published
Dey, L.P. a subsidiary
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in PG)
7 granted
19 published
Somerset Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
25 granted
0 published
MADAUS GMBH a subsidiary
DE, as the owner printed on each patent
18 granted
6 published
Mylan Laboratories Limited a subsidiary
named as the applicant on its applications, in IN. 1 more under the same name are not counted (printed in US)
0 granted
24 published
Oyster Point Pharma, Inc. a subsidiary
US, as the owner printed on each patent
18 granted
3 published
Meda Pharmaceuticals Inc. a subsidiary
US, as the owner printed on each patent
6 granted
4 published
MEDA AB a subsidiary
SE, as the owner printed on each patent
5 granted
3 published
Alphapharm Pty Ltd a subsidiary
AU, as the owner printed on each patent
3 granted
4 published
McDermott Laboratories Limited a subsidiary
IE, as the owner printed on each patent
3 granted
3 published
BGP Products Operations GmbH a subsidiary
CH, as the owner printed on each patent
3 granted
2 published
MYLAN TECHNOLOGIES, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
5 published
DPT Laboratories, Ltd. a subsidiary
US, as the owner printed on each patent
2 granted
2 published
GENERICS [UK] LIMITED a subsidiary
named as the applicant on its applications, in GB
0 granted
4 published
Alaven Pharmaceutical, LLC a subsidiary
US, as the owner printed on each patent
2 granted
1 published
MEDA OTC AB a subsidiary
named as the applicant on its applications, in SE
0 granted
3 published
MYLAN PHARMACEUTICALS ULC a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
Mylan Pharma UK Limited a subsidiary
GB, as the owner printed on each patent
0 granted
3 published
Viatris Asia Pacific Pte. Ltd. a subsidiary
named as the applicant on its applications, in SG
0 granted
3 published
Zpearpoint AS a subsidiary
NO, as the owner printed on each patent
2 granted
1 published
ABBEX AB a subsidiary
SE, as the owner printed on each patent
1 granted
1 published
Delcor Asset Corporation a subsidiary
named as the applicant on its applications, in US
0 granted
2 published
FAMYGEN LIFE SCIENCES, INC. a subsidiary
US, as the owner printed on each patent
2 granted
0 published
MEDA OTC AB a subsidiary
SE, as the owner printed on each patent
2 granted
0 published
Meda AB a subsidiary
named as the applicant on its applications, in SE
0 granted
2 published
Mylan Pharmaceuticals ULC a subsidiary
CA, as the owner printed on each patent
2 granted
0 published
AlphaPharm Pty Ltd a subsidiary
named as the applicant on its applications, in AU
0 granted
1 published
MYLAN IRELAND LIMITED a subsidiary
named as the applicant on its applications, in IE
0 granted
1 published
Mylan Pharma UK Limited a subsidiary
named as the applicant on its applications, in GB
0 granted
1 published
Viatris Inc. its own name
US, as the owner printed on each patent
0 granted
1 published
Names not counted (16)
Ipex AB
Most of its patents print JP; this name counts in SE. 83 granted and 51 published under it are not counted.
Ipex AB
Most of its patents print JP; this name counts in SE. 0 granted and 54 published under it are not counted.
Rottapharm Limited
Most of its patents print IT; this name counts in IE. 26 granted and 28 published under it are not counted.
EMD, Inc.
Most of its patents print JP; this name counts in US. 10 granted and 22 published under it are not counted.
Meda Pharma B.V.
Most of its patents print DE; this name counts in CH, NL. 13 granted and 10 published under it are not counted.
Viatris Inc
Most of its patents print DE; this name counts in US. 8 granted and 2 published under it are not counted.
EMD, Inc.
Most of its patents print JP; this name counts in US. 0 granted and 6 published under it are not counted.
Meda Pharma B.V.
Most of its patents print IT; this name counts in CH, NL. 0 granted and 6 published under it are not counted.
Rottapharm Limited
Most of its patents print IT; this name counts in IE. 0 granted and 6 published under it are not counted.
Mylan Group B.V.
Most of its patents print VN; this name counts in NL. 0 granted and 5 published under it are not counted.
Meda Pharma B.V.
Most of its patents print LU; this name counts in CH, NL. 2 granted and 2 published under it are not counted.
Dey, Inc.
No country is printed for it. 0 granted and 3 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 26, 202512,398,100Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamideOrganic fine chemistryMylan Laboratories Limited
Jun 17, 202512,329,934Devices for injecting medicaments and methods of useMedical technologyMcDermott Laboratories Limited
Dec 24, 2024D1,055,277Nasal spray guideOyster Point Pharma, Inc.
Dec 24, 2024D1,055,276Nasal spray guideOyster Point Pharma, Inc.
Oct 29, 202412,128,054Aqueous pharmaceutical compositions of prostaglandinsPharmaceuticalsFAMYGEN LIFE SCIENCES, INC.
Sep 24, 202412,098,018Nesting structures for storage, transport, and assembly of drug dispensers and containersHandlingOyster Point Pharma, Inc.
Jul 2, 202412,023,468Devices for injecting medicaments and methods of useMedical technologyMcDermott Laboratories Limited
Jul 2, 202412,023,344Topical otic, ophthalmic, and nasal corticosteroid formulationsPharmaceuticalsFAMYGEN LIFE SCIENCES, INC.
Feb 27, 202411,911,522Process for the continuous manufacture of a polyisobutylene based transdermal patchPharmaceuticalsMylan Inc.
Feb 27, 202411,911,380Compositions and use of varenicline for treating dry eyePharmaceuticalsOyster Point Pharma, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 20, 20252025/0352668AAV VECTOR ENCODING DIAMINE OXIDASE AND USES THEREOFPharmaceuticalsOyster Point Pharma, Inc.
Nov 20, 20252025/0352552PHARMACEUTICAL COMPOSITION COMPRISING MELOXICAMPharmaceuticalsMylan Laboratories Limited
Nov 20, 20252025/0352479PHARMACEUTICAL COMPOSITION COMPRISING MELOXICAMPharmaceuticalsMylan Laboratories Limited
Nov 20, 20252025/0352478PHARMACEUTICAL COMPOSITION COMPRISING MELOXICAMPharmaceuticalsMylan Laboratories Limited
Sep 25, 20252025/0295856DEVICES FOR INJECTING MEDICAMENTS AND METHODS OF USEMedical technologyMcDermott Laboratories Limited
Sep 4, 20252025/0275963DRY EYE TREATMENTSPharmaceuticalsOyster Point Pharma, Inc.
Aug 14, 20252025/0255865METHODS OF TREATING OCULAR CONDITIONSPharmaceuticalsOyster Point Pharma, Inc.
Jul 24, 20252025/0235449METHODS OF TREATING OCULAR CONDITIONSPharmaceuticalsOyster Point Pharma, Inc.
Jun 19, 20252025/0197904A PROCESS FOR THE SYNTHESIS OF ( R)-2-(( TERT-BUTOXYCARBONYL)AMINO)-3-(DIETHOXYPHOSPHORYL)PROPANOIC ACID OR OF PHOSPHONATE DERIVATIVES THEREOFOrganic fine chemistryViatris Asia Pacific Pte. Ltd.
May 22, 20252025/0163086Crystalline FormsPharmaceuticalsViatris Asia Pacific Pte. Ltd.
What it applied for, 2024 to 2025: Pharmaceuticals 16 · Medical technology 3 · Organic fine chemistry 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton VTRS · research, not advice